DTaP vaccine - Serum Institute of India

Drug Profile

DTaP vaccine - Serum Institute of India

Alternative Names: Acellular pertusis vaccines - Serum Institute of India; Diphtheria tetanus-acellular pertussis vaccine - Serum Institute of India

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Serum Institute of India
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 18 Jul 2017 Serum Institute of India completes a phase I trial for Diphtheria, Pertussis and Tetanus (Prevention) in India (IM) (CTRI2017-03-008003)
  • 04 Jul 2017 Serum completes enrolment in its phase I trial for Tetanus, Pertussis and Diphtheria (Prevention) in India before July 2017 (CTRI2017-03-008003)
  • 22 Mar 2017 Serum Institute of India plans a phase I trial for Diphtheria, Pertussis and Tetanus in India (CTRI2017-03-008003)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top